Back to top
more

Labcorp (LH)

(Delayed Data from NYSE)

$229.69 USD

229.69
406,776

-1.01 (-0.44%)

Updated Aug 29, 2024 04:00 PM ET

After-Market: $229.74 +0.05 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (175 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What's in Store for Edwards Lifesciences (EW) Q2 Earnings?

by Zacks Equity Research

Continued adoption of TruWave disposable pressure monitoring devices and progress in transfemoral EVOQUE and SAPIEN M3 platforms are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.

Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Improvement in demand at non-COVID business and continued strength in Bio-Rad's (BIO) Life Science segment are likely to have contributed to Q2 results.

LabCorp (LH) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Align Technology (ALGN) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Continued adoption of Invisalign Clear Aligners and iTero scanners are expected to have contributed to the Align Technology's (ALGN) second-quarter 2021 results.

Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Hologic's (HOLX) recent acquisitions and product launches are expected to contribute significantly to its third-quarter performance.

Boston Scientific (BSX) Watchman FLX Sales to Aid Q2 Earnings

by Zacks Equity Research

Strong procedure recovery and market share gains across many of the businesses and regions are expected to have boosted Boston Scientific's (BSX) Q2 sales.

Quest Diagnostics (DGX) Expands Testing Access With CLX Pact

by Zacks Equity Research

Quest Diagnostics' (DGX) COVID-19 testing will be available through TrustAssure platform for international travelers and live event attendants.

Cardinal Health (CAH) Introduces 2 New Digital Solutions

by Zacks Equity Research

Cardinal Health (CAH) launches NavixRx Compliance Packaging and E-Commerce Storefront to allow independent pharmacists to expand services and support medication adherence.

Integra (IART) Releases Favorable PriMatrix Clinical Outcome

by Zacks Equity Research

Integra's (IART) PriMatrix study data validates that one application of PriMatrix is needed to address hard-to-heal diabetic foot ulcers.

Base Test Rebound to Drive Quest Diagnostics (DGX) Q2 Earnings

by Zacks Equity Research

Quest Diagnostics' (DGX) second-quarter performance within its non-COVID base business might have registered significant sales rebound.

Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Are Investors Undervaluing LabCorp (LH) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

LH vs. CNMD: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

LH vs. CNMD: Which Stock Is the Better Value Option?

Lower COVID-19 Testing Demand to Drag Abbott (ABT) Q2 Earnings

by Zacks Equity Research

Apart from COVIG-19 test related hiccups, Abbott (ABT) is likely to have suffered from significant sales decline within its pediatric nutrition business in Q2.

Integra's (IART) SurgiMend Gets Innovative Technology Contract

by Zacks Equity Research

Integra's (IART) SurgiMend Collagen Matrix is recognized as a product that can potentially bring improvement to the health care industry.

Trina Mukherjee headshot

3 Stocks to Tap the Promising Dental Supplies Industry

by Trina Mukherjee

Despite the COVID-19 pandemic induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical-Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.

Thermo Fisher's (TMO) New Pact Drives Sustainable Lab Practices

by Zacks Equity Research

Thermo Fisher (TMO) expects to ACT label more than 1,200 additional SKUs to allow research, pharmaceutical and clinical laboratories to achieve their sustainability objectives.

Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio

by Zacks Equity Research

Investors are optimistic about Hill-Rom (HRC) on robust international growth and raised 2021 outlook.

Thermo Fisher's (TMO) Rapid DNA Solution Gets FBI Approval

by Zacks Equity Research

Thermo Fisher's (TMO) RapidHIT ID DNA Booking System allows seamless integration of Rapid DNA into the law enforcement booking agency process.

Here's Why You Should Add LabCorp (LH) Stock to Your Portfolio

by Zacks Equity Research

Investors are optimistic about LabCorp (LH) backed by strong diagnostic arm growth and improvement in base business.

What Makes Align Technology (ALGN) a Solid Choice Right Now?

by Zacks Equity Research

Strong performance and latest innovations in the Invisalign and iTero family are driving the top line for Align Technology (ALGN).

LabCorp (LH) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

LabCorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Urmimala Biswas headshot

5 Lucrative Picks Based on PEG Ratio for GARP Investors

by Urmimala Biswas

Here are five out of the 10 stocks, ASO, LB, PTR, LH, and HIBB, based on hybrid GARP investment strategy.

LabCorp (LH) Expands Testing Portfolio With the Launch of CDx

by Zacks Equity Research

LabCorp's (LH) new test expands the company's leadership in bringing testing solutions for new precision medicines used to treat patients with lung cancer.

Myriad Genetics (MYGN) Divests Myriad RBM to Focus on Core Units

by Zacks Equity Research

Myriad Genetics' (MYGN) new divesture will enable company to accelerate the execution of transformation plan and drive growth.